


CORRECTION **OPEN**

Correction to: Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Cornelius F. Waller , Julia Möbius and Adolfo Fuentes-Alburo

© The Author(s) 2024, corrected publication 2024

British Journal of Cancer (2024) 131:611; <https://doi.org/10.1038/s41416-024-02769-6>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-020-01255-z>, published online 16 February 2021

After publication of our article [1] we became aware that the Competing Interests statement was incomplete. It should read as follows: “C.F.W. is a consultant/advisory board member for Mylan Inc. A.F.-A. is a paid employee of Mylan Inc. and may hold stock with the company. J.M. is a paid employee of Mylan Healthcare GmbH in Hannover, Germany, and may hold stock with the company. Mylan Inc. produces trastuzumab for intravenous administration.”

The original article has been corrected.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024, corrected publication 2024

REFERENCE

1. Waller CF, Möbius J, Fuentes-Alburo A. Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice. *Br J Cancer*. 2021;124:1346–52. <https://doi.org/10.1038/s41416-020-01255-z>